Cardiac Dimensions’ Device Reduces Heart Failure In Trial
Executive Summary
Results of the 120-patient, sham-controlled REDUCE FMR trial showed Cardiac Dimensions Carillon device can significantly reduce mitral regurgitation and left ventricular volume in patients with symptomatic functional mitral regurgitation.
You may also be interested in...
CMS Proposes Coverage Policy For Transcatheter Edge-to-Edge Mitral Valve Repair
In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.
Cardiac Dimensions Launches IDE Trial of Carillon Mitral Repair System
The double-blind CARILLON trial will compare mechanical repair of functional mitral valve regurgitation with medical therapy alone in 400 patients at about 50 sites. The company is already running the REDUCE FMR randomized trial outside the US.
AMA Establishes Principles For ‘Augmented Intelligence’
The American Medical Association has written a set of principles for augmented intelligence (AI) development and deployment in health care. The organization hopes these principles can shape “a consistent governance structure for advancements in health care technology.”